IL-23 serum levels and IL23R polymorphisms in psoriasis: a meta-analysis of susceptibility and severity

Le résumé fourni par la source

BACKGROUND: Psoriasis is an immune-mediated inflammatory disease with a strong genetic basis. The Interleukin-23 (IL-23)/Th17 axis is central to its pathogenesis. While IL-23 is established, studies on systemic serum levels and IL23R gene polymorphisms yielded varied results. Our study clarified these associations through a systematic review and meta-analysis. METHODS: A systematic search was performed to find relevant studies. For serum IL-23, a random-effects model calculated overall Hedges’s g. For polymorphisms, pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for allelic, dominant, and recessive models. Heterogeneity (I² statistic) and sensitivity analyses were performed. RESULTS: Meta-analysis of serum IL-23 levels (six studies) showed no significant difference between patients and controls (Hedges’s g = -0.48, 95% CI: -1.58 to 0.62) with high heterogeneity (I² = 96.34%). For polymorphisms, the rs11209026 A allele showed a significant protective effect (OR = 0.52, p = 0.002). Conversely, rs2201841 increased psoriasis risk (OR = 1.39, p = 0.001), as did rs7530511 under the recessive model (OR = 1.29, p = 0.014). Significant associations were found between polymorphisms and both psoriasis severity (p < 0.001) and clinical type (p < 0.001). CONCLUSION: Our meta-analysis confirms a significant association between IL23R polymorphisms and susceptibility to psoriasis, with rs11209026 being protective and rs2201841 conferring risk. However, data does not support serum IL-23 as a reliable biomarker. This study widens the view toward personalized medicine and using polymorphisms as prognostic models.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.